

Open label trials			
open-label prospective study (41 patients with advanced cancer)	41 depressed (“are you depressed?”) patients enrolled; 30 completed the study	21/30 responded to 5 mg bid MPH after 3 days; a further 9 to 10 mg bid after 5 days.	(Homsí et al. 2001)
12-week open-label study (23 DAT patients with apathy)	initial scores >40 on the Apathy Evaluation Scale	significant improvement in apathy, depression, MMSE scores, and functional status	(Padala et al. 2010)
pilot study (10 patients)	patients with CRF	fatigue and depression scores improved rapidly to day 9, minimal improvement thereafter. 5 mg bid was optimal dose.	(Hardy et al. 2010)
open prospective trial (31 patients)	patients with advanced cancer and fatigue	MPH self-dosed up to 20 mg daily. Anxiety, appetite, pain, nausea, depression, and drowsiness all improved significantly (P <.05).	(Bruera et al. 2003)
pilot study of consecutive admissions (12 AD, 15 vascular dementia)	dementia patients with negative symptoms	Negative symptoms and cognitive scores improved significantly with MPH treatment	(Galynker et al. 1997)